Menu
Thor Medical ASA will present its financial results for the first half 2025 on Friday 29 August 2025 at 08:00 am (CET) at Sjølyst Møtesenter, Drammensveien 165, and welcome investors, analysts and media to review the company’s achievements in the first half and its vision for the road ahead.
The interim financial report for the first half 2025 and the presentation material will be released one hour earlier, at 07:00 (CET), and the material will also be available on the company website at www.thormedical.com.
While Thor Medical encourages physical attendance, the presentation and Q&A session will also be available through a live webcast at www.thormedical.com or through the following link: Thor Medical Webcast 1H 2025
Contacts:
Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com
About Thor Medical:
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'. To learn more, visit www.thormedical.com
